<?xml version="1.0" encoding="UTF-8"?>
<ref id="bb1085">
 <label>217</label>
 <element-citation publication-type="journal" id="rf1060">
  <person-group person-group-type="author">
   <name>
    <surname>Zhu</surname>
    <given-names>X.</given-names>
   </name>
   <name>
    <surname>Zhu</surname>
    <given-names>Y.</given-names>
   </name>
   <name>
    <surname>Ye</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Wang</surname>
    <given-names>Q.</given-names>
   </name>
   <name>
    <surname>Xu</surname>
    <given-names>W.</given-names>
   </name>
   <name>
    <surname>Su</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Sun</surname>
    <given-names>Z.</given-names>
   </name>
   <name>
    <surname>Yu</surname>
    <given-names>F.</given-names>
   </name>
   <name>
    <surname>Liu</surname>
    <given-names>Q.</given-names>
   </name>
   <name>
    <surname>Wang</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Zhang</surname>
    <given-names>T.</given-names>
   </name>
  </person-group>
  <article-title>Improved pharmacological and structural properties of HIV fusion inhibitor AP3 over enfuvirtide: highlighting advantages of artificial peptide strategy</article-title>
  <source>Sci. Rep.</source>
  <volume>5</volume>
  <issue>1</issue>
  <year>2015</year>
  <fpage>1</fpage>
  <lpage>5</lpage>
  <comment>Aug 19</comment>
 </element-citation>
</ref>
